Sunday, March 12, 2017 12:41:03 AM
I do own a good number of shares in USRM. I invested prior to the latest Form 8-K filing and the settlement with Northstar. This transaction with GAPC has raised a lot of questions in my mind. I simply want a better understanding of the results of the deal with GACP before I decide to add more to, or liquidate my USRM holdings.
I am not surprised that my questions have rankled a few feathers. But I believe my questions posted on this board are valid and therefore hopefully receive a well educated response. I know that legal documents can be long and difficult to understand, but I believe many on this board do not correctly understand what USRM has done with their agreement with GACP.
Would it change any investor's opinion of their USRM investment if it is true that USRM sold off their stem cell bank business (at least for the life of the lease with GAPC). I don't know enough about the existing and future profits generated from this part of the business. It might make good sense to jettison less important parts of the business and focus on the FDA products like MyoCell®, MyoCell SDF-1 and AdipoCell. Perhaps even a suitor doesn't want all the ancillary business units and only these products.
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM